Everolimus Footings Characterized
Depending on their self-rating, all patients were assigned to one of five groups (none, mild, moderate, severe, and very severe), and the analysis of variance (anova) trend test (one degree of freedom) was used to test for a linear relationship between these groups and increasing AE-QoL scores. Taking into account the limited group sizes, we decided to not compute tests of significance between the five groups Cilengitide but to present the results of a descriptive analysis including mean and standard deviation of each group. To test the ability of AE-QoL to yield stable scores over a short period of time, the AE-QoL was administered twice in a subsample of 46 patients. The time interval between both AE-QoL administrations was three weeks. The results of the domain scores and total scores were compared by computing the interclass correlation coefficient. An interclass coefficient of?>?0.70 indicates good reproducibility [7]. To detect drivers of AE-QoL scores (domain scores and total score), multiple linear regression analysis (stepwise) was used. Age, gender, and patients�� self-rated disease activity were set as independent variables, and the AE-QoL domain scores or its total score was set as dependent variables. All statistical analyses were performed using spss (IBM SPSS Statistics Version 19, IBM Everolimus concentration Corporation, Armonk, NY, USA). P?Palbociclib range 19�C85?years) participated in the item reduction and AE-QoL validation. The sociodemographic and clinical data of this sample are shown in Table?1. While the current guideline classification [18] regards patients with recurrent angioedema without C1-inhibitor deficiency and without wheals as a subset of chronic spontaneous urticaria, we decided to list the latter as a separate group. The reason is that these patients clinically differ from those urticaria patients who develop recurrent wheals in addition to angioedema, and this might be important for the interpretation of our results. To obtain information on the attack frequency, the participating patients were asked, at the time of completion of the AE-QoL items, when the last swelling episode had occurred. Response options (chosen by n of patients) were ��today or yesterday�� (n?=?29), ��during the last week�� (n?=?31), ��between 1 and 4?weeks ago�� (n?=?23), ��between 4?weeks and 3?months ago�� (n?=?10), and ��more than 3?months ago�� (n?=?6). Eleven patients provided no answer to this question. The item generation phase resulted in 29 items possibly relevant to patients with recurrent angioedema, each covering a recall period of 4?weeks. For item reduction, the impact of each item was computed (Table?2). Items 21 to 23 and 26 to 28 were removed, because their impact scored?
